|[September 02, 2013]
Research and Markets: Immunotherapy in Oncology Drug Pipeline Update 2013 Contains Identified Drugs Linked to 413 Different Targets
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/76jnds/immunotherapy_in)
has announced the addition of the "Immunotherapy
in Oncology Drug Pipeline Update 2013" report to their offering.
Cancer immunotherapy offers an attractive therapeutic addition,
delivering treatment of high specificity, low toxicity and prolonged
activity. In this Drug Pipeline Update BioSeeker brings together the
fields of antibodies, vaccines, and immunostimulators in oncology drug
development into one source.
There are today 571 companies plus partners developing 1007 cancer
immunotherapy drugs in 2500 developmental projects in cancer. In
addition, there are 17 suspended drugs and the accumulated number of
ceased drugs over the last years amount to another 474 drugs.
Immunotherapy In Oncology Drug Pipeline pdate lists all drugs and gives
you a progress analysis on each one of them. Identified drugs are linked
to 413 different targets. All included targets have been
cross-referenced for the presence of mutations associated with human
cancer. To date 387 out of the 391 studied drug targets so far have been
recorded with somatic mutations. The software application lets you
narrow in on these mutations and links out to the mutational analysis
for each of the drug targets for detailed information. All drugs targets
are further categorized on in the software application by 65
classifications of molecular function and with pathway referrals to
BioCarta, KEGG, NCI-Nature and NetPath.
All targets are cross-referenced with the Catalogue of Somatic Mutations
in Cancer (COSMIC). It is designed to store and display somatic mutation
information and related details and contains information relating to
human cancers. To date 387 out of the 391 studied drug targets so far
have been recorded with somatic mutations and the software application
lets you narrow in on these mutations and links out to the mutational
analysis for each of the drug targets for detailed information.
The identity of available biological structures on 243 drug targets was
retrieved from the RCSB Protein Databank for you to easily review the
2733 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/76jnds/immunotherapy_in
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]